Pharmacogenomic drug screening provides a promising platform for the discovery of anti-cancer drugs, in combination with biomarkers and mechanisms that confer therapeutic response. A study now pinpoints the mechanisms of sensitivity to dasatinib in T-ALL leukemia, identifying a T cell–differentiation switch that determines sensitivity to distinct drug modalities.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 /Â 30Â days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Batlle, E. & Clevers, H. Nat. Med. 23, 1124–1134 (2017).
Sharma, A. et al. Nat. Commun. 9, 4931 (2018).
Cordó, V., van der Zwet, J. C. G., Canté-Barrett, K., Pieters, R. & Meijerink, J. P. P. Blood Cancer Discov 2, 19–31 (2020).
Lee, J.-K. et al. Nat. Genet. 50, 1399–1411 (2018).
Tyner, J. W. et al. Nature 562, 526–531 (2018).
Chia, S. et al. Nat. Commun. 8, 435 (2017).
Frismantas, V. et al. Blood 129, e26–e37 (2017).
Gocho, Y. et al. Nat. Cancer https://doi.org/10.1038/s43018-020-00167-4 (2021).
Greuber, E. K., Smith-Pearson, P., Wang, J. & Pendergast, A. M. Nat. Rev. Cancer 13, 559–571 (2013). 9.
Chonghaile, T. N. et al. Cancer Discov. 4, 1074–1087 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Skanderup, A.J., DasGupta, R. Targeting the developmental origins of cancer. Nat Cancer 2, 256–257 (2021). https://doi.org/10.1038/s43018-021-00186-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-021-00186-9
